UNSPSC 51343811: Abacavir/dolutegravir/lamivudine

This classification denotes a combination drug for treatment of HIV. The first component, ABACAVIR, has US FDA Unique Ingredient Identifier of WR2TIP26VS. The second component, DOLUTEGRAVIR, has US FDA Unique Ingredient Identifier of DKO1W9H7M1. The third component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95.

UNSPSC 51343811 Abacavir/dolutegravir/lamivudine is a Commodity code identifying a fixed-dose combination antiretroviral medication for HIV treatment. State and local procurement activity under this code is minimal; the recent-opportunities block contains no relevant solicitations for this pharmaceutical product. The opportunities tagged to this code in the source include a county purchasing department relocation notice, a naloxone and drug deactivation systems procurement for emergency medical services, a reverse trade show networking event, a forensic drug standards solicitation, a pharmaceutical RFP for a multistate cooperative purchasing alliance, and several vendor forums and networking events—none of which involve procurement of abacavir/dolutegravir/lamivudine or HIV treatment medications. The code appears inactive in state and local government contracting based on available recent opportunities.

A single tangential opportunity—MMCAP's January 20, 2026 RFP for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026)—falls under pharmaceutical procurement but does not specify HIV antiretrovirals as part of its scope and instead targets generic commodities through a multistate cooperative purchasing vehicle administered by the Minnesota Department of Administration. Without documented recent solicitations for abacavir/dolutegravir/lamivudine by state agencies, counties, cities, school districts, or other local bodies, no geographic concentration, repeat-buyer pattern, or representative opportunity can be characterized for this specific Commodity code.